Please login to the form below

Not currently logged in
Email:
Password:

JPA adds to Washington team

Jeff Goldfarb to join PR agency as VP
JPA Jeff Goldfarb

JPA Health Communications has expanded its Washingtom team with the appointment of Jeff Goldfarb as VP.

Goldfarb has two decades' experience in marketing, branding and communications, said JPA, with significant experience in the healthcare industry. He joins from Matthews Media Group (MMG).

As VP and senior strategist at MMG, Goldfarb developed communications plans and ran patient recruitment initiatives of clinical trials. He also managed public health communications programmes for the Food and Drug Administration and National Cancer Institute.

Before joining MMG, Goldfarb worked on marketing programmes for products such as Claritin and Glucophage. He previously worked for the agency Trahan, Burden, Charles where he managed marketing objectives for the likes of Blue Cross Blue Shield of Maryland and the Baltimore Ravens.

In his new role Goldfarb will 'lead several client projects, participate in new business efforts and support staff development', JPA told PMLiVE. He will support pharmaceutical clients and non-profit organisations, and will start out with a team of four.

“We are thrilled to welcome Jeff to the agency,” said Carrie Jones, principal and managing director of JPA. “His extensive communications experience in the healthcare industry will help us deliver the high-quality results our clients expect.”

30th January 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...